Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q3 2021 · 10-Q
Revenue$23.48M$23.48M+54.3% vs Q3 2020 Net Income-$11.79M-$11.79MN/M vs Q3 2020 EPS Diluted-$0.47-$0.47N/M vs Q3 2020 Operating Income-$11,814,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,060,000N/M Margins · derivedOperating margin-50.3%−24.7 pt vs Q3 2020
Net margin-50.2%−20.1 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 8, 2021 · 39 d after period end